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Abstract
Objective: Epidemiological studies on the association of serum oestradiol levels and inflamma-
tory markers have reported inconsistent and conflicting results. Therefore, we investigated the
association between serum oestradiol and high-sensitivity C-reactive protein (CRP) levels in
women on the basis of their menopausal status.
Methods: This cross-sectional study examined the association between serum oestradiol and
CRP levels on the basis of menopausal status in 151 premenopausal women aged 42.7 6.7 years
and 394 postmenopausal women aged 58.1 6.7 years who participated in a health examination
program. Multiple linear regression analysis was conducted using CRP levels as the dependent
variable.
Results: Multiple linear regression analysis showed that serum oestradiol levels were inversely
associated with CRP levels in premenopausal women (b coefficient¼0.298) after adjusting for
age, body mass index, smoking, mean arterial pressure, and levels of fasting plasma glucose,
triglycerides, high-density lipoprotein cholesterol, aspartate aminotransferase, and alanine ami-
notransferase. However, this association was not found in postmenopausal women after adjusting
for the same confounding factors.
Conclusions: Serum oestradiol levels are inversely associated with CRP levels in premenopausal
women, but not in postmenopausal women. Lower oestrogenic activity may at least partly con-
tribute to the pathogenesis of chronic inflammation, particularly in premenopausal women.
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Introduction
Cardiovascular disease (CVD) is caused by
multifactorial interrelated mechanisms,
among which chronic low-grade inflamma-
tion plays a major role.1 In women, meno-
pause is an important contributing factor to
CVD in addition to traditional risk factors,
including obesity, hypertension, type 2 dia-
betes, and dyslipidaemia.2 Postmenopausal
women are more susceptible to weight gain
and visceral fat accumulation accompanied
by a marked decrease in oestrogen levels.3
These changes influence lipid metabolism
and the vascular endothelium,4 increasing
the risk of atherosclerotic CVD in postmen-
opausal women.5
Current evidence supports the existence
of sex-specific relationships between sex
hormones and inflammatory markers.
There is a consistent inverse relationship
between serum testosterone levels and
inflammatory markers in men.6,7 However,
epidemiological studies that investigated
the association between serum oestradiol
levels and inflammatory markers in
women, particularly when categorized by
menopausal status, have shown inconsistent
and even conflicting results. Some observa-
tional studies found a positive association
of serum oestradiol levels and inflammatory
markers in postmenopausal women8,9 and
an inverse association in premenopausal
women,10,11 whereas others did not show
significant relationships between these vari-
ables.12 Although the reasons for this dis-
crepancy among studies are not clear, the
effects of endogenous oestrogen on chronic
low-grade inflammation may differ by men-
opausal status.
C-reactive protein (CRP) has tradition-
ally been considered a non-specific marker
of inflammation, but recent epidemiological
evidence has highlighted the significance of
high CRP levels in patients with CVD
through cross-sectional and longitudinal
studies.13 We hypothesized that serum oes-
trogen levels play differing roles in inflam-
mation according to menopausal status.
Therefore, this study aimed to investigate
the association between serum oestradiol
and CRP levels in women while taking
into account their menopausal status.
Methods
Study participants
We reviewed the medical records of 689
women who voluntarily visited the Health
Promotion Center of Gangnam Severance
Hospital, for a routine health check-up,
between November 2013 and July 2015.
Natural menopause was defined as the
absence of menstrual periods for 12 consec-
utive months. The exclusion criteria were as
follows: current intake of oral contracep-
tives; exogenous oestrogen replacement;
history of tamoxifen therapy; induced men-
opause, including bilateral oophorectomy-,
radiation-, or drug-induced menopause;
history of ischaemic heart disease or cere-
brovascular, thyroid, respiratory, renal,
liver, or rheumatological disease; missing
data; and no fasting for 12 hours before
testing (n¼ 81). Of the remaining partici-
pants, those with a CRP level 10mg/L
were excluded to rule out the possibility of
infection or an inflammatory disorder
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(n¼ 9). We also excluded women who
reported irregular menstruation over the
previous year to rule out the possibility of
polycystic ovarian syndrome or perimeno-
pause (n¼ 54). Written informed consent
was obtained from each participant. This
study was conducted in accordance with
the ethical principles of the Declaration of
Helsinki and was approved by the institu-
tional review board of Yonsei University
Gangnam Severance Hospital (institutional
review board number: 3-2019-0267).
Data collection
Each participant completed a self-reported
questionnaire on lifestyle habits and men-
strual and medical history. Cigarette smok-
ing, alcohol consumption, and physical
activity were determined on the basis of
responses. Cigarette smoking was defined
as a current habit of smoking. Alcohol
drinking was defined as alcohol consump-
tion on 2 or more days per week. Regular
exercise was defined as engaging in pur-
poseful physical activity three or more
times per week. Menstrual history was
determined by the response to the following
question: “Has there been menstruation for
1 or more years?” with three response
options. These response options were as fol-
lows: “yes,” “no, but there has been inter-
mittent menstruation over the last year,”
and “no, there has been no menstruation.”
Medical examinations were performed by
trained medical staff using a standardized
procedure. Body weight and height were
measured to the nearest 0.1 kg and 0.1
cm, respectively, and participants wore
light indoor clothing without shoes. Body
mass index (BMI) was calculated as the
weight in kilograms divided by the square
of the height in meters (kg/m2). Systolic
blood pressure (SBP) and diastolic blood
pressure (DBP) were measured using the
patient’s right arm with a standard mercury
sphygmomanometer (Baumanometer;
W.A. Baum Co Inc., Copiague, NY,
USA). Mean arterial pressure was calculat-
ed using the following equation: SBPþ 2
DBP)/3.
All blood samples were obtained from
the antecubital vein after fasting for 12
hours. Fasting plasma glucose, triglycer-
ides, high-density lipoprotein (HDL) cho-
lesterol, aspartate aminotransferase (AST),
and alanine aminotransferase (ALT) levels
were measured via enzymatic methods
using the AU5800 automated chemistry
analyser (Beckman Coulter, Fullerton,
CA, USA). Serum oestradiol levels were
measured by electrochemiluminescence
immunoassay using the Cobas e601 immu-
noanalyser (Roche Diagnostics, Basel,
Switzerland). In the present study, serum
oestradiol levels were measured because
there is strong agreement between serum
and plasma oestrogen levels.14 High-
sensitivity CRP levels were measured using
the Roche/Hitachi 912 System (Roche
Diagnostics, Indianapolis, IN, USA) with
a latex-enhanced immunoturbidimetric
method with a lower limit of detection of
0.02 mg/L.
Statistical analysis
Normal distribution of data was evaluated
with determination of skewness using the
Kolmogorov–Smirnov test. Triglyceride,
AST, ALT, oestradiol, and CRP levels
had a skewed distribution. The clinical
characteristics of the cohort were compared
by menopausal status using the indepen-
dent two-sample test or the Wilcoxon
rank-sum test for continuous variables
taking into account normality of distribu-
tion, and the chi-squared test was used for
categorical variables. Continuous data are
presented as the mean standard deviation
or median (interquartile range), whereas
categorical data are presented as
frequency. Pearson’s correlation was used
to examine bivariate correlations between
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log-transformed CRP levels and clinical
variables. Multiple linear regression analy-
sis was conducted with the log-transformed
CRP level as the dependent variable to
examine the independent association
between oestrogen and CRP levels. In this
analysis, model 1 was adjusted for age and
BMI. Model 2 was adjusted for age, BMI,
cigarette smoking, mean arterial pressure,
and levels of fasting plasma glucose, log-
transformed triglyceride, and high-density
lipoprotein-cholesterol. Model 3 was adjust-
ed for age, BMI, cigarette smoking, mean
arterial pressure, and levels of fasting
plasma glucose, log-transformed triglycer-
ides, high-density lipoprotein cholesterol,
log-transformed AST, and log-transformed
ALT. All analyses were conducted using
SAS statistical software (version 9.4; SAS
Institute Inc., Cary, NC, USA). All
statistical tests were two-sided and a P val-
ue< 0.05 was considered statistically
significant.
Results
Table 1 shows the clinical and biochemical
characteristics of 545 participants who were
included in the final analysis, including 151
premenopausal women and 394 postmeno-
pausal women, by menopausal status. The
mean standard deviation age of the pre-
menopausal women was 42.7 6.7 years
(range: 21–52 years), whereas that of the
postmenopausal women was 58.1 6.7
years (range: 46–75 years). The mean age,
BMI, blood pressure, and fasting plasma
glucose levels, and the median triglyceride,
AST, ALT, and CRP levels were signifi-
cantly higher in postmenopausal women





(n¼ 394) P value
Age (years) 42.7 6.7 58.1 6.7 <0.001
BMI (kg/m2) 21.5 3.1 23.1 3.0 <0.001
SBP (mmHg) 114.6 17.8 124.8 19.1 <0.001
DBP (mmHg) 70.5 11.1 76.0 11.0 <0.001
MAP (mmHg) 85.2 12.9 92.3 13.2 <0.001
FPG (mmol/L) 4.83 0.63 5.30 1.01 <0.001
Triglycerides (mmol/L) 0.76 (0.58–1.09) 0.90 (0.74–1.38) <0.001
HDL cholesterol (mmol/L) 1.53 0.32 1.41 0.35 <0.001
AST (U/L) 17 (15–20) 21 (18–25) <0.001
ALT (U/L) 14 (11–18) 19 (15–26) <0.001
C-reactive protein (mg/L) 0.49 (0.30–1.00) 0.70 (0.32–1.50) <0.001
Oestradiol (pmol/L) 442.4 (205.6–742.6) 29.4 (18.4–45.2) <0.001
Current smoking (%) 6.9 2.7 0.061
Alcohol drinking (%) 20.4 12.3 0.017
Regular exercise (%) 30.4 40.0 0.044
Data are expressed as mean standard deviation, median (interquartile range), or %.
P values were calculated using the independent two sample t-test or the Wilcoxon rank-sum test for continuous variables
on the basis of normality of distribution, or the chi-squared test for categorical variables.
Alcohol drinking refers to consuming alcohol on 2 or more days per week. Regular exercise refers to activity three or
more times per week.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial blood pressure;
FPG, fasting plasma glucose; HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
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than in premenopausal women (all
P< 0.001). However, mean HDL cholesterol
and median oestradiol levels were significant-
ly lower in postmenopausal women than in
premenopausal women (both P< 0.001).
Table 2 shows the results of Pearson’s cor-
relation analysis between log-transformed
CRP levels and clinical variables. Log-
transformed CRP levels were significantly
correlated with BMI, SBP, log-transformed
triglyceride levels, log-transformed AST
levels, and log-transformed oestradiol levels
in premenopausal women (all P< 0.05). In
postmenopausal women, log-transformed
CRP levels were significantly correlated with
age, BMI, SBP, DBP, mean arterial pressure,
and levels of fasting plasma glucose, log-
transformed triglycerides, HDL cholesterol,
log-transformed AST, and log-transformed
ALT (all P< 0.001). However, log-
transformed CRP levels were not correlated
with log-transformed oestradiol levels.
Table 3 shows the results of multiple
linear regression analysis of the indepen-
dent relationship between oestradiol and
CRP levels. Log-transformed oestradiol
levels were inversely associated with log-
transformed CRP levels only in premeno-
pausal women (P< 0.01 for all three
models). However, log-transformed oestra-
diol levels were not associated with log-
transformed CRP levels in postmenopausal
women after adjusting for age, BMI,
cigarette smoking, mean arterial pressure,
and levels of fasting plasma glucose,
log-transformed triglycerides, HDL
cholesterol log-transformed AST, and log-
transformed ALT.
Discussion
We found that serum oestradiol levels were
inversely and independently associated with
CRP levels in premenopausal women after
adjusting for potential confounding varia-
bles. However, there was no such inverse
relationship in postmenopausal women.
Our findings are consistent with the results
of previous studies, which showed that oes-
tradiol levels were inversely associated with
Table 2. Correlation between log-transformed CRP levels and clinical variables.
Premenopausal women Postmenopausal women
r P value r P value
Age (years) 0.075 0.372 0.186 <0.001
BMI (kg/m2) 0.294 <0.001 0.388 <0.001
SBP (mmHg) 0.167 0.045 0.187 <0.001
DBP (mmHg) 0.115 0.189 0.178 <0.001
MAP (mmHg) 0.140 0.094 0.188 <0.001
FPG (mmol/L) 0.058 0.490 0.169 <0.001
Triglycerides (mmol/L)* 0.313 <0.001 0.168 <0.001
HDL cholesterol (mmol/L) 0.144 0.085 0.234 <0.001
AST (U/L)* 0.107 0.020 0.190 <0.001
ALT (U/L)* 0.149 0.074 0.198 <0.001
Oestradiol (pmol/L)* 0.303 <0.001 0.008 0.872
P values were calculated using Pearson’s correlation analysis.
*Indicates log-transformed values.
CRP, C-reactive protein; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean
arterial blood pressure; FPG, fasting plasma glucose; HDL, high-density lipoprotein; AST, aspartate aminotransferase; ALT,
alanine aminotransferase.
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inflammatory markers in premenopausal
women.10,11
Previous studies on the association
between oestradiol levels and inflammatory
markers in women were inconclusive. Using
the BioCycle Study dataset, Gaskins et al.10
reported an inverse association between
oestradiol and CRP levels in 259
reproductive-aged women in the United
States, which is consistent with the findings
of our study. In contrast, serum oestradiol
levels were positively associated with CRP
levels in 513 Italian postmenopausal women
who were investigated in the Invecchiare in
Chianti study.9 Therefore, additional longi-
tudinal studies are warranted to establish
the relationship between serum oestradiol
and CRP levels on the basis of menopausal
status.
The mechanism underlying the
menopause-specific relationship between
serum oestradiol and CRP levels remains
unclear. Oestrogen has an inhibitory effect
on inflammatory cytokine production and
inflammatory cell migration in non-
reproductive tissues,15,16 and oestrogen
receptors are highly expressed in vascular
smooth muscle and endothelial cells
throughout the human body.16,17
Oestrogen’s anti-inflammatory effects are,
in part, mediated by nitric oxide production
and cytokine suppression15 because nitric
oxide is a key vasodilator.18,19 Nitric oxide
also plays an anti-inflammatory role in the
endothelium owing to its role as a reactive
oxygen species scavenger and an inhibitor
of leukocyte recruitment.20–22 Moreover,
oestrogen decreases levels of tumour necro-
sis factor-a, which is a major pro-
inflammatory cytokine.23 These cascades
potentially inhibit the synthesis and release
of platelet-activating factors and chemo-
kines, including interleukin-6, and may
also down-regulate leukocyte-recruiting
adhesion molecules, including intercellular
adhesion molecule-1, vascular cell adhesion
molecule-1, and E-selectin.24–26 Oestrogen
could also decrease production of reactive
oxygen species in mitochondria, and this
reduces chronic low-grade inflamma-
tion.27,28 However, these effects of oestra-
diol may differ with the menopausal
status. The lack of an inverse relationship
between oestradiol and CRP levels in post-
menopausal women may be explained by
the observation that 80% of circulating oes-
tradiol in such individuals originates from
aromatization of testosterone, especially in
adipose tissue.9,29 Aromatase, which is an
enzyme that converts testosterone into oes-
tradiol, is stimulated by inflammatory cyto-
kines and CRP.
There are several limitations of this
study. First, this study had a cross-
sectional design. Therefore, the results
should be interpreted while taking into
account causal and temporal considera-
tions. Additional longitudinal studies are
Table 3. Multiple linear regression analysis of the
independent relationship between log-transformed






Model 1 0.301 0.088 <0.001
Model 2 0.295 0.087 <0.001
Model 3 0.298 0.084 0.001
Postmenopausal women
Model 1 0.004 0.066 0.949
Model 2 0.016 0.070 0.818
Model 3 0.018 0.070 0.799
b refers to the standardized beta coefficient.
Model 1: adjusted for age and body mass index.
Model 2: adjusted for age, body mass index, cigarette
smoking, mean arterial pressure, and levels of fasting
plasma glucose, log-transformed triglycerides, and high-
density lipoprotein cholesterol.
Model 3: adjusted for age, body mass index, cigarette
smoking, mean arterial pressure, and levels of fasting
plasma glucose, log-transformed triglycerides,
high-density lipoprotein cholesterol, log-transformed
aspartate aminotransferase, and log-transformed alanine
aminotransferase.
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required to establish causality between
serum oestradiol and CRP levels based on
menopausal status. Second, the study par-
ticipants included only women who under-
went routine health screening at a single
hospital. Therefore, these women may
have comprised a relatively healthier pro-
portion of the community and our cohort
may not be representative of the general
population. Third, oestradiol levels were
measured by electrochemiluminescence
immunoassay and not by liquid
chromatography-mass spectrometry, even
though the latter is considered the best
method for measuring serum oestradiol
levels. However, the electrochemilumines-
cence immunoassay method has several
advantages, including a rapid turnaround
time, high-throughput, and full automa-
tion. Fourth, serum oestradiol and CRP
levels may fluctuate during the menstrual
cycle.30 We did not measure serum oestra-
diol levels and CRP levels at a common
point during the cycle in our premeno-
pausal participants. Fifth, other sex hor-
mones, such as testosterone, were not
measured in the present study. Further
studies are required to determine the rela-
tionship between other sex hormones and
inflammatory markers while taking into
account menopausal status. Finally,
although CRP is currently considered a reli-
able biomarker of chronic inflammation,13
caution is required when assuming anti- or
pro-inflammatory activity based only on
this biomarker because we did not directly
quantify other serum inflammatory
markers, such as tumour necrosis factor-a
and interleukin-6, to support our findings.
Despite these limitations, this study has
several strengths. We assessed the associa-
tion between serum oestradiol and CRP
levels in premenopausal and postmeno-
pausal women separately. This may provide
useful insight into the association between
serum oestradiol and CRP levels on the
basis of menopausal status. Moreover, a
wide range of confounding factors closely
related to chronic inflammation, including
BMI, smoking status, blood pressure, fast-
ing plasma glucose levels, triglyceride levels,
HDL-cholesterol levels, and hepatic
enzymes, were considered when performing
multiple linear regression analyses.
Additionally, to determine the true nature
of the relationship between oestradiol and
CRP levels in pre- and postmenopausal
women, our study excluded participants
with induced or secondary menopause, as
well as women who used oral contraceptives
or who were undergoing oestrogen replace-
ment therapy. Induced menopause causes a
sudden onset of obesity and metabolic dis-
turbance followed by an abrupt decline in
ovarian hormones, which could cause
chronic inflammation.31
In conclusion, our data show that serum
oestradiol levels are inversely associated
with CRP levels in premenopausal women,
but not in postmenopausal women. Our
findings suggest that lower oestrogenic
activity may at least partly contribute to
the pathogenesis of chronic inflammation,
particularly in premenopausal women.
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